唐氏综合征与阿尔茨海默病:生物标志物、临床症状与病理机制
综述指出唐氏综合征患者因APP基因三拷贝必然发生阿尔茨海默病病理,40岁前几乎全部出现病理改变,54岁左右约70%诊断为痴呆,终生风险95%。其临床与生物标志物轨迹类似晚发型与常染色体显性阿尔茨海默病,但进展更快,且为理想研究人群。目前三项针对该人群的疾病修饰治疗试验正在进行。
要点
- 唐氏综合征患者40岁前几乎均出现AD病理,54岁约70%痴呆,终生风险95%。
- AD是35岁以上唐氏综合征成人主要死因,临床与生物标志物轨迹可精准分期。
- 该人群AD进展快于晚发型或常染色体显性AD,支持开展疾病修饰治疗试验。
核心结论
- 唐氏综合征因APP基因三拷贝决定必然发生AD,是研究晚发型AD生物机制与试验治疗的理想人群。
研究设计与样本
- 综述综合近10年唐氏综合征与AD交叉领域研究证据,未报告系统检索范围。
主要发现
- 唐氏综合征患者40岁前几乎全部出现AD病理,54岁左右约70%诊断为痴呆,终生风险95%。
- AD是35岁以上唐氏综合征成人主要死因。
- 唐氏综合征相关AD的临床与生物标志物轨迹类似晚发型AD和常染色体显性AD,但进展更快。
临床怎么用
- 对唐氏综合征成人应关注AD临床与生物标志物分期,并了解其进展快于其他AD类型。
局限性
- 原文未报告综述检索策略与纳入研究的具体样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individuals with Down syndrome have a genetically determined form of Alzheimer's disease, due to an additional copy of the APP gene. Nearly all individuals with Down syndrome develop Alzheimer's disease pathology by age 40 years, and approximately 70% are diagnosed with dementia by around age 54 years, with an overall lifetime risk of 95%. Moreover, Alzheimer's disease is the leading cause of death in adults with Down syndrome older than 35 years. RECENT DEVELOPMENTS: The intersection of Down syndrome and Alzheimer's disease has garnered substantial attention in the past 10 years as research indicates that the trajectory of clinical symptoms and biomarker changes in adults with Down syndrome closely resembles that seen in late-onset Alzheimer's disease and autosomal-dominant Alzheimer's disease (ADAD). The predictive nature of dementia onset in genetically determined populations allows precise staging of disease in individuals along the Alzheimer's disease continuum. The high prevalence of Alzheimer's disease pathology combined with the few age-related comorbidities in these cohorts, makes them ideal for understanding the biological mechanisms related to late-onset Alzheimer's disease. The more rapid disease progression seen in people with Down syndrome-related Alzheimer's disease compared with people with ADAD or late-onset Alzheimer's disease provides important insights and supports the rationale for new clinical trials. WHERE NEXT?: The Alzheimer's Clinical Trials Consortium-Down Syndrome is ushering in a new era of therapies for individuals with Down syndrome. Three ongoing clinical trials, in close collaboration with industry partners, specifically designed for this population, are focused on testing disease-modifying treatments. These innovative efforts mark a considerable stride in bringing groundbreaking therapies to a group that has long been excluded from clinical trials in Alzheimer's disease.
引用
- Rafii MS, Schlachetzki Z, Barroeta I, et al. Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology. Lancet Neurol. 2025. PMID: 40818475. doi:10.1016/S1474-4422(25)00237-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。